Arakis and Vectura announce start of phase IIb trial of NVA237 for COPD

19-Oct-2005

Turnkey biobank for the cryopreservation of biological samples

High-performance hybrid silica for preparative chromatography

The smart solution for filling and labeling your HPLC, cryo and micro tubes

Arakis Ltd. , a wholly-owned subsidiary of Sosei Co. Ltd. , and Vectura Group plc announced that their collaborative product, NVA237 (formerly AD 237), a novel inhaled once daily treatment for chronic obstructive pulmonary disease (COPD), has entered a Phase IIb multiple dose-ranging clinical trial. NVA237 is being developed and commercialised by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol (QAB149), under the terms of the agreement signed in April 2005.

The study is a randomised, double-blind, multi-centre, placebo-controlled trial designed to evaluate the efficacy, safety and dose response of NVA237 in patients diagnosed with COPD over a four week period.

https://www.bionity.com/en/news/49645/arakis-and-vectura-announce-start-of-phase-iib-trial-of-nva237-for-copd.html